Companies are marrying gene editing with stem cell therapies in new clinical trials.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Pauling, L. et al. Science 110, 543–548 (1949).
Sankaran, V. J. et al. Science 322, 1839–1842 (2008).
Xu, J. et al. Science 334, 993–996 (2011).
Tisdale, J. F et al. ASH Annual Meeting & Exposition abstr. 1026 (2018).
Esrick, E. B. et al. ASH Annual Meeting & Exposition abstr. 1023 (2018).
Canver, M. C. et al. Nature 527, 192–197 (2015).
Tisdale, J.F et al. ASH Annual Meeting & Exposition abstr. 1026 (2018).
Esrick, E.B. et al. ASH Annual Meeting & Exposition abstr. 1023 (2018).
Finn, J. D. et al. Cell Rep. 22, P2227–P2235 (2018).
Deuse, T. et al. Nat. Biotechnol. 37, 252–258 (2019).
Kosicki, M. et al. Nat. Biotechnol. 36, 765–771 (2018).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Azvolinsky, A. Molecular scissors cut in on stem cells. Nat Med 25, 864–866 (2019). https://doi.org/10.1038/s41591-019-0467-6
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41591-019-0467-6